14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VRDN vs MESO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (36.8/100 SELL vs. 35.5/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. VRDN trades at $30.22 (1.0x Forward P/E, -1781.4% operating margin) versus MESO at $12.47 (N/M Forward P/E, -42.6% operating margin).
Growth vs. Quality Trade-Off: VRDN earns the overall head-to-head edge with a stronger Unified Composite Score (36.8/100 SELL vs. MESO 35.5/100 SELL) and 1.12β · 64% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although VRDN compares more favorably head-to-head, both VRDN (36.8/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRDN vs MESO. Trailing 12-month operating profitability (VRDN -1781.4% vs MESO -42.6%) and valuation multiples (VRDN 1.0x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VRDN vs MESO Key Questions & Quantitative Answers
As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (36.8/100 SELL vs. 35.5/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. VRDN trades at $30.22 (1.0x Forward P/E, -1781.4% operating margin) versus MESO at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: VRDN earns the overall head-to-head edge with a stronger Unified Composite Score (36.8/100 SELL vs. MESO 35.5/100 SELL) and 1.12β · 64% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although VRDN compares more favorably head-to-head, both VRDN (36.8/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VRDN trades in a Markup technical trend (SURGE options phase, RSI 72.2); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MESO leads the Growth & Scale pillar: VRDN posts -63.5% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (N/A gross margin, -1781.4% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, VRDN generates $26M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, VRDN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.
VRDN screens cheaper on headline valuation multiples. VRDN trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and 134.2x EV/Revenue (unreported FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRDN (-83.7% ROE) versus MESO (-9.9% ROE) capital efficiency.
In options market volatility and institutional positioning, VRDN carries 87.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.12β · 64% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.